![]() ![]() The percentage of outstanding shares held by the insiders is 1.25% while it is 95.80% for the institutional holders. Number of outstanding shares of the stock stood at 226.97 million. Having a second look at Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) provides that stock’s average daily trading volume for 3 months was 3.71 million, while it jumped to 1.87 million when we calculate an average volume for past 10 days. On the other hand, the S&P 500 Index was down -1.45% in the last trading session while the Dow Jones Industrial closed the session lower at -1.07%. Horizon Therapeutics Public Limited Company has a P/E ratio of 49.63 against that of Pfizer Inc.’s 7.20 while GSK plc is showing 12.84 for the same. (PFE) which saw its stock price fall by -0.18% in the last trading and went through a decrease of -19.20% in past 12-month trading. In comparing Horizon Therapeutics Public Limited Company (HZNP)’s stock with other industry players reveals that stock’s current price change of 0.36% and that of 8.82% over the past 12 months is in competing position with that of Pfizer Inc. Long term indicators are suggesting an average of 100% Buy for it. In contrast, when we review HZNP stock’s current outlook then short term indicators are assigning it an average of 50% Buy, while medium term indicators are categorizing the stock at an average of 50% Buy. In last 7 days, analysts came adjusting their opinions about stock’s EPS with no upward and no downward revisions, an indication which could give clearer idea about the company’s short term price movement. In keeping analyst consensus estimate with, company is forecasted to be making an annual revenue of $3.61 billion in 2022, which will be 11.70% more from revenue generated by the company last year. The average estimate is representing a decrease of -9.00% in sales growth from that of posted by the company in the same quarter of last year. They suggested that in the process company could generate revenue of as low as $912.75 million which could climb up to $935 million to hit a high. These estimates are suggesting current year growth of 3.00% for EPS and 13.70% growth next year.Īnalysts watching the company’s growth closely have provided estimates for its revenue growth with an average revenue estimate of $922.92 million. with estimates of that growing to $5.41 in next year. Analysts are in estimates of $1.09 per share for company’s earnings in the current quarter and are expecting its annual EPS growth moving up to $4. With its current market valuation of $25.18 billion, Horizon Therapeutics Public Limited Company is set to declare its quarterly results on Mar 01, 2023. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Mobile payments are projected to boom into a massive $12 trillion market by 2028. Will You Miss Out On This Growth Stock Boom?Ī new megatrend in the fintech market is well underway. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |